At the news
? NEUTRALIMPACT 2/10 CLUSTER filed Aug 6, 2026 at 18:44 ET
Three executives at Corcept Therapeutics sold a combined $3.88M in open-market stock over a 7-day window, including the CFO and Chief Development Officer. At a $12B market cap, this represents ~0.03%, a trivial proportion, making it routine portfolio diversification rather than a bearish signal. The sales follow recent option exercises and align with typical vesting-related liquidity patterns.
- Three insiders sold $3.88M total in open-market sales over 7 days.
- Total sales represent ~0.03% of the $12.0B market cap.
- CFO Atabak Mokari sold 9,000 shares ($958K) at $106.96.
- Sean Maduck sold 20,305 shares ($2.33M) at $114.70 after exercising options.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access